These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38236008)

  • 61. A systematic review and meta-analysis of studies evaluating the performance of point-of-care tests for human papillomavirus screening.
    Kelly H; Mayaud P; Segondy M; Pant Pai N; Peeling RW
    Sex Transm Infect; 2017 Dec; 93(S4):S36-S45. PubMed ID: 29223961
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Frequency of Human papillomavirus in women attending cervical cancer screening program in Chile.
    Brebi P; Ili CG; Andana A; Menzel D; Lopez J; Guzman P; Melo A; Buchegger K; Roa JC
    BMC Cancer; 2017 Aug; 17(1):518. PubMed ID: 28774281
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Diagnostic Performance of HPV E6/E7 mRNA and HPV DNA Assays for the Detection and Screening of Oncogenic Human Papillomavirus Infection among Woman with Cervical Lesions in China.
    Wang HY; Lee D; Park S; Kim G; Kim S; Han L; Yubo R; Li Y; Park KH; Lee H
    Asian Pac J Cancer Prev; 2015; 16(17):7633-40. PubMed ID: 26625774
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in Beijing, China: analysis of results from China's top 3 hospital, 2009-2019.
    Liu Y; Ang Q; Wu H; Xu J; Chen D; Zhao H; Liu H; Guo X; Gu Y; Qiu H
    Virol J; 2020 Jul; 17(1):104. PubMed ID: 32660490
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evaluation of high-risk human papillomavirus types PCR detection in paired urine and cervical samples of women with abnormal cytology.
    Daponte A; Pournaras S; Mademtzis I; Hadjichristodoulou C; Kostopoulou E; Maniatis AN; Messinis IE
    J Clin Virol; 2006 Jul; 36(3):189-93. PubMed ID: 16690350
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Presence of human papillomavirus infection of the uterine cervix as determined by different detection methods in a low-risk community-based population.
    Zazove P; Reed BD; Gregoire L; Gorenflo DW; Lancaster WD; Ruffin MT; Hruszczyk J
    Arch Fam Med; 1993 Dec; 2(12):1250-8. PubMed ID: 8130906
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [A comparison of human papillomavirus detection and ThinPrep cytology test for women in Guangdong province].
    Xue YH; Chen ZX; Zheng BW; Zhang JM; Zhu QY
    Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):283-5. PubMed ID: 15996320
    [TBL] [Abstract][Full Text] [Related]  

  • 68. HPV testing in primary screening of older women.
    Cuzick J; Beverley E; Ho L; Terry G; Sapper H; Mielzynska I; Lorincz A; Chan WK; Krausz T; Soutter P
    Br J Cancer; 1999 Oct; 81(3):554-8. PubMed ID: 10507785
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Cervical cancer screening: past--present--future].
    Breitenecker G
    Pathologe; 2009 Dec; 30 Suppl 2():128-35. PubMed ID: 19756616
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
    Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
    PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Assessment of a New Lower-Cost Real-Time PCR Assay for Detection of High-Risk Human Papillomavirus: Useful for Cervical Screening in Limited-Resource Settings?
    Fokom Domgue J; Schiffman M; Wentzensen NH; Gage JC; Castle PE; Raine-Bennett TR; Fetterman B; Lorey T; Poitras NE; Befano B; Xie Y; Miachon LS; Dean M
    J Clin Microbiol; 2017 Aug; 55(8):2348-2355. PubMed ID: 28515214
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Human papillomavirus detection using the Abbott RealTime high-risk HPV tests compared with conventional nested PCR coupled to high-throughput sequencing of amplification products in cervical smear specimens from a Gabonese female population.
    Moussavou-Boundzanga P; Koumakpayi IH; Labouba I; Leroy EM; Belembaogo E; Berthet N
    Virol J; 2017 Dec; 14(1):241. PubMed ID: 29268766
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Importance of the Pap smear in the age of HPV testing].
    Ghisu GP
    Ther Umsch; 2021; 78(2):93-98. PubMed ID: 33615865
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Leveraging COVID-era innovation for cervical cancer screening: Clinician awareness and attitudes toward self-sampling and rapid testing for HPV detection.
    Rodriguez NM; Brennan LP; Claure L; Balian LN; Champion VL; Forman MR
    PLoS One; 2023; 18(3):e0282853. PubMed ID: 36893182
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cervical high-risk human papillomavirus infection among women residing in the Gulf Cooperation Council countries: Prevalence, type-specific distribution, and correlation with cervical cytology.
    Ali MAM; Bedair RN; Abd El Atti RM
    Cancer Cytopathol; 2019 Sep; 127(9):567-577. PubMed ID: 31390155
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical Performance of Human Papillomavirus Testing and Visual Inspection With Acetic Acid in Primary, Combination, and Sequential Cervical Cancer Screening in China.
    Wang MZ; Feng RM; Wang S; Duan XZ; Li D; Zhang X; Mu R; Qiao Y; Smith JS
    Sex Transm Dis; 2019 Aug; 46(8):540-547. PubMed ID: 31295223
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force.
    Whitlock EP; Vesco KK; Eder M; Lin JS; Senger CA; Burda BU
    Ann Intern Med; 2011 Nov; 155(10):687-97, W214-5. PubMed ID: 22006930
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Human papillomavirus testing in primary cervical screening and abnormal Papanicolaou management.
    Cox JT
    Obstet Gynecol Surv; 2006 Jun; 61(6 Suppl 1):S15-25. PubMed ID: 16729900
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample study.
    Preisler S; Rebolj M; Ejegod DM; Lynge E; Rygaard C; Bonde J
    BMC Cancer; 2016 Jul; 16():510. PubMed ID: 27439470
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Impact of high-risk Human Papillomavirus genotyping in cervical disease in the Northern region of Portugal: Real-world data from regional cervical cancer screening program.
    Rosário A; Sousa A; Marinho-Dias J; Medeiros R; Lobo C; Leça L; Coimbra N; Tavares F; Baldaque I; Martins G; Monteiro P; Henrique R; Sousa H
    J Med Virol; 2023 Jan; 95(1):e28414. PubMed ID: 36541747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.